12:00 AM
Mar 30, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GMI-1070: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial (GMI-1070-101) in 40 healthy volunteers showed that single ascending-doses of GMI-1070 produced no serious adverse...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >